Skip to main content

Product Development Pipeline

Our development pipeline is strategically focused on advancing a portfolio of products that target significant unmet needs in mental health and anxiety treatment.

Program

Mechanism of Action

Indication

Commercial Stage

KRN 101
(Psilocybin)
Pharma
Serotonin receptor agonist, promoting neuroplasticity
Complex Anxiety and PTSD Treatment as an Adjunct Medicine
Pre Clinical
D8/CBN
Nasal Mist
Pharma
Mild psychoactive cannabinoid with anxiolytic properties
Complex anxiety and PTSD treatment as an Adjunct Medicine
Anecdotal Evidence, Patent filed
Kava Inhaler Pharma
Kavalactones enhance GABA receptor binding via Pulmonary Delivery
Panic Attack Disorder; Anxiety induced Insomnia; Smoking Cessation
Anecdotal Evidence, Patent filed
Kava Wellness
Kavalactones enhance gaba receptor binding
Promotes non-addictive calm and sleep
NPN filed
Kanna
Wellness
Serotonin reuptake inhibition and PDE4 modulation for mood elevation
Boosts mood, focus, and energy, lacks severe side effects of SSRIs
NPN Filed
Catuaba
Wellness
Dopamine and serotonin modulation; aphrodisiac and neuroprotective effects
Enhances vitality, libido, and overall well-being
NPN Filed
CBN
Wellness
Non-psychoactive cannabinoid binding to CB1/CB2 receptors for sedative and anti-anxiety effects
Natural sleep aid and relaxation promoter; enhances daily wellness without dependency
NPN Filed
Patent Acquired

Patents

Provisional Patent Applications and Supporting Research

D8/CBN (Provisional Patent Filed)

"Pharmaceutical-Grade Delta-8-THC and Cannabinol Delivery Systems for Adjunct Psychotherapeutic Treatment of Complex PTSD and Trauma-Focused Interventions"
Anecdotal Evidence of efficacy in PTSD Patients and other Cannabis Assisted Psychoterapy (CAP). Potential for General Anxiety and Insomnia Treatments

KAVA (Provisional Patent Filed)

"Pulmonary and Nasal Delivery of Kava Extract
for Promoting Calm, Rapid Treatment of
Anxiety, Insomnia, Addiction Disorders,
and Benzodiazepine-Contraindicated
Conditions with Enhanced Safety Profile"
Supporting research includes pharmacokinetic studies of inhaled kava, safety assessments, and clinical data on anxiolytic and sedative outcomes.

CBN
(US Patent Number 9,763,991)

"Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders (ADHD), and Post-Traumatic Stress Disorders (PTSD)"
The invention relates to a composition for use in the treatment of neurobehavioral disorders utilizing various Cannabis plant extracts comprising Cannabinol (CBN) preferably with other constituents of this plant for such use and a method for the extraction of plants